Netskope enters its September 2 earnings date down 12% on the week and sitting 23% below the Street's average price target — a gap that makes the stock look either cheap or simply unloved by the market, even as analysts keep lifting their numbers.
The analyst revision cycle is the clearest ongoing thread. Since the previous note on August 19, the bidding has continued. JP Morgan's Brian Essex raised his target to $16 from $14 on August 26 — the most recent action from a bellwether firm — while Keybanc followed Oppenheimer and Wells Fargo in lifting targets earlier in the week. The consensus target now runs at $17.53, against a close of $13.50. That 30% implied upside is unusually wide, and it hasn't budged the stock. The previous note flagged this pattern at $15.37; the price has since fallen further while targets have moved higher. Eleven buys and two holds remain the Street lineup. The bulls cite strong net new ARR growth and SASE market positioning. Bears point to quarterly execution volatility and margin pressure from intensifying competition.
Positioning looks loose rather than charged, which adds a layer of interest to the week's price drop. Short interest jumped 16% in a single session on August 25 to around 13.7 million shares — the sharpest daily move in months — but still only half the late-July peak above 28 million. The borrow market reflects the same relaxed tone: cost to borrow is just 0.68%, up 47% on the week but still firmly at the low end of any historical range. Availability is generous at 348%, meaning roughly three shares are available to lend for every one already borrowed. That combination of rising short interest and ample borrow suggests new shorts can enter without friction — this is not a squeeze setup. The ORTEX short score of 51, while edging higher, sits in neutral territory and ranks in only the 25th percentile for the sector.
Options traders are similarly calm ahead of the print. The put/call ratio at 0.46 is almost exactly in line with its 20-day average of 0.45, with a z-score barely above zero. The 52-week high on the PCR is 0.52 — the current reading is nowhere near defensive territory. That's a notable contrast to the stock being down 12% on the week. Cybersecurity peers had a rough week too: CRWD fell 13% and S dropped nearly 10%. PATH bucked the sector, gaining 7%. The sector-wide weakness provides some cover for NTSK's slide, but the stock's 1-month gain of 17% means it came in elevated relative to where it started August.
The earnings history sharpens the focus on September 2. The three most recent prints produced first-day moves of -2.5%, -3.2%, and -17%. That last reading, from June 3, came alongside a five-day loss of nearly 30%. The pattern is asymmetric: the stock has shown it can absorb mild misses without lasting damage — the July 7 report saw a -2.5% day-one move followed by a 17% five-day recovery — but a genuine miss carries meaningful downside tail risk. With the stock already down sharply into the event and institutional holders including Canada Pension Plan doubling their position in Q2, the setup heading into September 2 is less about short positioning and more about whether the quarter delivers on the trajectory analysts have been pricing in.
See the live data behind this article on ORTEX.
Open NTSK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
